Following a rough January, corporate buybacks should start to support the market in February, while more reasonable valuations offer reasons to be more positive about the long-term prospects for speculative tech stocks.
The last day of January was everything the rest of the month wasn’t – stocks were up, the Nasdaq led the gains, and Cathie Wood’s ARK Innovation ETF (ARKK—the poster child for high-multiple, high-promise, as-yet-unprofitable tech, i.e. speculative or “spec” tech) was up 9.5%.1 After a major reset, could this bounce be a sign of things to come in February? Could the Nasdaq bounce and could “spec tech” outperform?
Broadly, January’s sell-off cleared a lot of pandemic-era froth – in valuations and positioning. For example, the Nasdaq forward price-to-earnings multiple reset to 26.5x from a peak of 34x on January 26, 2021.2 Tech became an underweighted sector. The Federal Reserve’s more hawkish tone caused a repricing higher in yields. Now with this needed reset behind us, we are starting with a much cleaner slate and can focus on the positives.
One such positive is the return in February of the largest buyer in the markets—corporates making discretionary share buybacks. Most of the S&P 500 was in a blackout period until January 24 due to earnings reporting requirements, but by the end of this week 70% of S&P 500 market cap is projected to be out of blackout.3 This number will rise further in the coming weeks. Given the degree of corrections in many stocks, many companies may accelerate buyback plans. Corporate buybacks are expected to reach $872 billion in 2022, outpacing last year’s $808 billion.4 This could be a significant source of support for the markets, starting this month.
Can “spec tech” also bounce back? In the short term (the next few weeks or months), it is overdue for a tactical bounce and potentially a short squeeze; in the medium term (the duration of the Fed tightening cycle) we do not expect the space to be a big outperformer; in the long term (three years-plus), we believe these companies could become profitable, grow into their valuations, and outperform as a result. Here are some reasons why.
Short term: “Spec tech” is due for a tactical bounce
Despite the S&P 500 barely correcting 10%, ARKK—taken as a proxy for “spec tech”—is roughly 50% lower than its 52-week high in mid-February 2021.5 Last week, technical indicators on the ARKK fund screened as oversold, as they last did in March 2020. The fund’s options skew—a measure of fear in the market—was in the 92nd percentile over the last five years.6 Its median stock multiple, as measured by price-to-sales, fell from 14.3x on November 9, 2021, to 8.2x as of January 31, only slightly higher than the 6.5x recorded back on April 9, 2020.7
As a result, the median stock in the fund is now forecast to have 86% upside to the consensus analyst price target.8 Sure, another bout of Fed-induced uncertainty could pressure valuations further but without a Fed meeting until March, and given the reset in prices and outflows from growth stocks in January, a tactical bounce is likely. Finally, short interest in ARKK is at a record 17%, against 12% for the Nasdaq 100. In the event of a tactical bounce, it could force those with short positions to close them out, causing a short squeeze and pushing the price up further.9
Medium term: Tightening cycle caps outperformance potential
The big driver of outperformance of “spec tech” has been the rise in valuations, which more than doubled from April 2020 to November 2021.10 A valuation re-rating should not be expected amid a Fed tightening cycle. History suggests that multiples typically stay either range-bound or compress somewhat (we wrote about this in our 2022 Outlook).11
This implies that earnings will have to rise to spur a resurgence. However, many high-promise innovation-based stocks remain unprofitable. For example, the median stock in the ARKK ETF had adjusted earnings per share (EPS) of negative $0.34, and if you exclude Tesla, Zoom, Coinbase, and Shopify, it falls to negative $0.41.12
The burden therefore falls on revenue growth to drive performance. However, revenue growth could slow for many “spec tech” stocks over the next couple of years because the pull forward in demand spurred by the pandemic is likely not repeatable. Coupled with uncertainties around multiples, we would not expect a repeat of their 2020 outperformance. Finally, equity returns for factors such as growth, momentum, risk, and small-cap—which are applicable to many “spec tech” stocks—tend to be muted during the tightening phase of the cycle, with little differentiation between these factors.13
Longer term: Bullish on expectation that companies grow into their valuations
Despite the recent underperformance, it should be noted that themes like gene therapy, automation and robotics, artificial intelligence, Web 3.0, and fintech innovation, among others, are not fads but long-term secular themes that are already changing and shaping our future. Companies that are building this future and are little known today could eventually become household names. However, for them to outperform they either need a tangible catalyst (like the pandemic was for many digital stocks) or time to grow into their valuations and turn from “spec tech” to “profitable tech”. Indeed, the ARK Innovation ETF’s median adjusted EPS is projected to improve from negative $0.34 to $0.00 by 2024.14
For investors focused on the longer term, we recommend buying into innovation stocks when their price drops and more broadly staying the course, but being prepared for periodic pullbacks after period of outperformance. Of course, stock and/or fund selection is still key to long-term success. We also recommend looking to private markets. Venture capital-backed companies are accessing the same innovation megatrends but even earlier in the companies’ lifecycle, thereby capturing more of their hypergrowth phase. This is why venture capital is one of our top investment ideas for hypergrowth in 2022. For a more detailed analysis, please see our 2022 Outlook.
Was this article helpful?
YesNo
(1) Source: Bloomberg, as of January 31, 2022.
(2) Source: Bloomberg, as of January 31, 2022.
(3) Source: Goldman Markets Division, January 31, 2022.
(4) Source: Compustat, Goldman Sachs Investment Research, as of December 2, 2021.
(5) Source: Bloomberg, as of January 31, 2022.
(6) Source: Bloomberg, as of January 26, 2022.
(7) Source: iCapital Investment Strategy, Bloomberg, as of January 31, 2022
(8) Source: iCapital Investment Strategy, Bloomberg, as of January 31, 2022
(9) Source: Bloomberg, as of January 31, 2022.
(10) Source: Bloomberg, as of January 31, 2022.
(11) Source: iCapital Investment Strategy, Bloomberg, as of December 31, 2021
(12) Source: iCapital Investment Strategy, Bloomberg, as of January 31, 2022
(13) Source: Bank of America Quantitative Research, as of January 28, 2022
(14) Source: iCapital Investment Strategy, Bloomberg, as of January 31, 2022
IMPORTANT INFORMATION
This material is provided for informational purposes only and is not intended as, and may not be relied on in any manner as legal, tax or investment advice, a recommendation, or as an offer to sell, a solicitation of an offer to purchase or a recommendation of any interest in any fund or security offered by Institutional Capital Network, Inc. or its affiliates (together “iCapital”). Past performance is not indicative of future results. Alternative investments are complex, speculative investment vehicles and are not suitable for all investors. An investment in an alternative investment entails a high degree of risk and no assurance can be given that any alternative investment fund’s investment objectives will be achieved or that investors will receive a return of their capital. The information contained herein is subject to change and is also incomplete. This industry information and its importance is an opinion only and should not be relied upon as the only important information available. Information contained herein has been obtained from sources believed to be reliable, but not guaranteed, and iCapital assumes no liability for the information provided.
This presentation contains forward looking statements. Forward looking statements include, but are not limited to assumptions, estimates, projections, opinions, models and hypothetical performance analysis. Forward looking statements involve significant elements of subjective judgments and analyses and changes thereto and/or consideration of different or additional factors could have a material impact on the results indicated. Due to various risks and uncertainties, actual results may vary materially from the results contained herein. No representation or warranty is made by iCapital as to the reasonableness or completeness of such forward looking statements or to any other financial information contained herein.
Products offered by iCapital are typically private placements that are sold only to qualified clients of iCapital through transactions that are exempt from registration under applicable securities laws, including the Securities Act of 1933 pursuant to Rule 506(b) of Regulation D promulgated thereunder (“Private Placements”). An investment in any product issued pursuant to a Private Placement, such as the funds described, entails a high degree of risk and no assurance can be given that any alternative investment fund’s investment objectives will be achieved or that investors will receive a return of their capital. Further, such investments are not subject to the same levels of regulatory scrutiny as publicly listed investments, and as a result, investors may have access to significantly less information than they can access with respect to publicly listed investments. Prospective investors should also note that investments in the products described involve long lock-ups and do not provide investors with liquidity.
iCapital may have issued, and may in the future issue, material that is inconsistent with, and reaches different conclusions from, the information presented in this document. Those documents reflect the different assumptions, views, and analytical methods of the analysts who prepared them and iCapital is under no obligation to ensure that such other reports are brought to the attention of any recipient of this document.
Securities may be offered through iCapital Securities, LLC, a registered broker dealer, member of FINRA and SIPC and subsidiary of Institutional Capital Network, Inc. (d/b/a iCapital). These registrations and memberships in no way imply that the SEC, FINRA or SIPC have endorsed the entities, products or services discussed herein. iCapital is a registered trademark of Institutional Capital Network, Inc. Additional information is available upon request.
Anastasia Amoroso is a Managing Director and the Chief Investment Strategist at iCapital. In this role, she is responsible for providing insight on private and public market investing opportunities for advisors and their high-net-worth clients. Previously, Anastasia was an Executive Director and the Head of Cross-Asset Thematic Strategy for J.P. Morgan Private Bank, where she identified and invested in emerging technologies and disruptive trends such as artificial intelligence, decarbonization, and gene therapy. She also developed global tactical ideas and implemented institutional-level implementation across asset classes for clients. Anastasia regularly appears on CNBC and Bloomberg TV and is often quoted in the financial press. See Full Bio.
-AnnuitiesAccess educational resources on annuity products. Learn more about fixed annuities, fixed indexed annuities, structured annuities, and variable annuities.
We use cookies and other technologies to collect data about your browser, device and location. We share this data with advertising, social media and analytics partners to help us understand how the site is used and to personalize our content and the advertising you see on this and other sites. By clicking “Accept”, you consent to the use of ALL the cookies. See our Cookie Policy here.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience. See our Cookie Policy Here.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
__hssrc
session
This cookie is set by Hubspot whenever it changes the session cookie. The __hssrc cookie set to 1 indicates that the user has restarted the browser, and if the cookie does not exist, it is assumed to be a new session.
_GRECAPTCHA
5 months 27 days
This cookie is set by the Google recaptcha service to identify bots to protect the website against malicious spam attacks.
ASP.NET_SessionId
session
Issued by Microsoft's ASP.NET Application, this cookie stores session data during a user's website visit.
cookielawinfo-checkbox-analytics
1 year
Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional
1 year
The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary
1 year
Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-performance
1 year
Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".
viewed_cookie_policy
1 year
The cookie is set by the GDPR Cookie Consent plugin to store whether or not the user has consented to the use of cookies. It does not store any personal data.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Cookie
Duration
Description
__hstc
5 months 27 days
This is the main cookie set by Hubspot, for tracking visitors. It contains the domain, initial timestamp (first visit), last timestamp (last visit), current timestamp (this visit), and session number (increments for each subsequent session).
_ga
2 years
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_FYHL2MPPTT
2 years
This cookie is installed by Google Analytics.
_gcl_au
3 months
Provided by Google Tag Manager to experiment advertisement efficiency of websites using their services.
_gid
1 day
Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
hubspotutk
5 months 27 days
HubSpot sets this cookie to keep track of the visitors to the website. This cookie is passed to HubSpot on form submission and used when deduplicating contacts.
LiveBall
1 year
This cookie is created on pages that contain a custom ION component, which embeds interactive content on the site. It stores user ID and respondent ID values for each unique visitor. The cookie does not store any Personal Data. This persistent cookie expires after one year.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Cookie
Duration
Description
__cf_bm
30 minutes
This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.
__hssc
30 minutes
HubSpot sets this cookie to keep track of sessions and to determine if HubSpot should increment the session number and timestamps in the __hstc cookie.
AnalyticsSyncHistory
1 month
Used to store information about the time a sync took place with the LinkedIn lms_analytics cookie.
bcookie
2 years
LinkedIn sets this cookie from LinkedIn share buttons and ad tags to recognize browser ID.
bscookie
2 years
LinkedIn sets this cookie to store performed actions on the website.
lang
session
LinkedIn sets this cookie to remember a user's language setting.
li_gc
2 years
Used to store consent of guests regarding the use of cookies for LinkedIn non-essential purposes.
lidc
1 day
LinkedIn sets the lidc cookie to facilitate data center selection.
UserMatchHistory
1 month
LinkedIn sets this cookie for LinkedIn Ads ID syncing.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Cookie
Duration
Description
_gat
1 minute
This cookie is installed by Google Universal Analytics to restrain request rate and thus limit the collection of data on high traffic sites.